“…BRAF V600E immunohistochemistry was positive only in the LCH (Figure 1I), consistent with the subclonal allele frequency. Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1 , but not in TSC2 1–3 . Pancreatic WD‐NET, on the contrary, demonstrate frequent mutations in MEN1 , DAXX , ATRX , and TSC2 , but not in BRAF 4–6 …”
Section: Figurementioning
confidence: 99%
“…Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1 , but not in TSC2 . 1 , 2 , 3 Pancreatic WD‐NET, on the contrary, demonstrate frequent mutations in MEN1 , DAXX , ATRX , and TSC2 , but not in BRAF . 4 , 5 , 6 …”
mentioning
confidence: 97%
“…Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1, but not in TSC2. [1][2][3] Pancreatic WD-NET, on the contrary, demonstrate frequent mutations in MEN1, DAXX, ATRX, and TSC2, but not in BRAF. [4][5][6] This is an unusual case of metastatic WD-NET with coexisting LCH, highlighting that adult LCH often co-occurs with other malignancies.…”
mentioning
confidence: 99%
“…[4][5][6] This is an unusual case of metastatic WD-NET with coexisting LCH, highlighting that adult LCH often co-occurs with other malignancies. [1][2][3] The patient received peptide receptor radionuclide therapy for WD-NET (LCH not treated) and has been alive >1 year post-biopsy.…”
This is an unusual adult case of a metastatic well‐differentiated neuroendocrine tumor with incidentally discovered subtle involvement of Langerhans cell histiocytosis (LCH), a clonal proliferation of Langerhans cells. It is important to recognize that LCH can often co‐exist with other malignancies (solid > hematologic).
“…BRAF V600E immunohistochemistry was positive only in the LCH (Figure 1I), consistent with the subclonal allele frequency. Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1 , but not in TSC2 1–3 . Pancreatic WD‐NET, on the contrary, demonstrate frequent mutations in MEN1 , DAXX , ATRX , and TSC2 , but not in BRAF 4–6 …”
Section: Figurementioning
confidence: 99%
“…Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1 , but not in TSC2 . 1 , 2 , 3 Pancreatic WD‐NET, on the contrary, demonstrate frequent mutations in MEN1 , DAXX , ATRX , and TSC2 , but not in BRAF . 4 , 5 , 6 …”
mentioning
confidence: 97%
“…Furthermore, LCH are known to harbor frequent mutations in BRAF p.V600E or MAP2K1, but not in TSC2. [1][2][3] Pancreatic WD-NET, on the contrary, demonstrate frequent mutations in MEN1, DAXX, ATRX, and TSC2, but not in BRAF. [4][5][6] This is an unusual case of metastatic WD-NET with coexisting LCH, highlighting that adult LCH often co-occurs with other malignancies.…”
mentioning
confidence: 99%
“…[4][5][6] This is an unusual case of metastatic WD-NET with coexisting LCH, highlighting that adult LCH often co-occurs with other malignancies. [1][2][3] The patient received peptide receptor radionuclide therapy for WD-NET (LCH not treated) and has been alive >1 year post-biopsy.…”
This is an unusual adult case of a metastatic well‐differentiated neuroendocrine tumor with incidentally discovered subtle involvement of Langerhans cell histiocytosis (LCH), a clonal proliferation of Langerhans cells. It is important to recognize that LCH can often co‐exist with other malignancies (solid > hematologic).
“…У больных, перенесших ГКЛ, в дальнейшем отмечается более высокая, чем в среднем по популяции, частота Обзор литературы Review развития злокачественных заболеваний, которая достигает среди взрослых уровня 32% [10]. При этом наиболее часто диагностируются различные формы лейкозов [11].…”
Relevant information on Langerhans cell histiocytosis development and course in children is presented. The current concepts of disease pathogenesis, principles of its severity evaluation, patients stratification into risk groups, as well as of clinical course features are described. Modern approaches to the disease treatment via targeted therapy are summarized and analyzed.
This case report describes a woman in her 30s who had been treated with chemotherapy and presented with Langerhans cell histiocytosis and acute myeloid leukemia (AML).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.